Furthermore, BCR-ABL fusion protein 210 kDa is illustrated with 90% of CML, which induces malignant transformation through inhibition of cell adhesion, apoptosis, and differentiation [9]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.